来氟米特联合激素治疗狼疮性肾炎疗效观察

目的:观察来氟米特(LEF)治疗狼疮性肾炎的有效性及安全性.方法:对15例诊断明确的狼疮性肾炎患者运用LEF联合激素治疗24周,在治疗的8周、12周、24周测定24 h尿蛋白定量、血浆白蛋白、肾功能及自身抗体和不良反应.结果:LEF治疗24周尿蛋白完全缓解和部分缓解分别为57%和30%(P＜0.01).白蛋白显著升高至正常(P＜0.01).ANA滴度明显下降 24周时转阴93.3%,ds-DNA阴转率93.3%,ANCA阴转率100%.狼疮活动明显控制,SLEDAI评分显著下降(P＜0.01),均低于9分.结论:LEF是治疗狼疮性肾炎一种安全有效的药物.     

阿魏酸哌嗪治疗狼疮肾炎疗效观察

目的观察阿魏酸哌嗪片治疗狼疮肾炎的临床疗效。方法将80例狼疮肾炎患者随机分为两组。对照组给予激素加免疫抑制剂常规治疗。治疗组在对照组基础上加用阿魏酸哌嗪片治疗。观察并比较两组的临床疗效及血肌酐、尿素氮、血浆白蛋白、血红蛋白、尿蛋白定量、补体C3、抗核抗体、抗双链DNA抗体等指标的改变情况。结果治疗组在治疗后血尿素氮、血肌酐、尿蛋白定量均明显下降,血浆白蛋白、血红蛋白较治疗前明显上升,且与对照组比较有统计学差异。结论阿魏酸哌嗪联合激素加免疫抑制剂治疗狼疮肾炎疗效优于常规治疗,对狼疮肾炎患者纠正贫血、改善肾功能、降低尿蛋白有一定疗效。     

肾炎康复片治疗糖尿病肾病的疗效观察

目的:研究肾炎康复片治疗早中期糖尿病肾病的疗效.方法:采用随机、对照的方法将经临床确诊为Ⅲ、Ⅳ期糖尿病肾病的患者60例分为肾炎康复片治疗组和洛汀新对照组,每组各30例.治疗组给予肾炎康复片(薄膜衣片)每次5粒,每日3次口服;对照组给予洛汀新10 mg,每日1次口服,疗程均为2月.观察治疗前后两组临床症状积分、肾功能、尿微量白蛋白排泄率或24 h尿蛋白定量、血C反应蛋白和尿转化生长因子β1的变化.结果:对Ⅳ期糖尿病肾病,肾炎康复片组与洛汀新组的总有效率分别为73.3%和46.7%,肾炎康复片组较洛汀新组疗效显著(P＜0.05),提示肾炎康复片在改善糖尿病肾病患者临床症状方面明显优于对照组.经肾炎康复片治疗的Ⅳ期糖尿病肾病的尿蛋白则明显减少(P＜0.05).Ⅲ期、Ⅳ期糖尿病肾病经肾炎康复片治疗后其血C反应蛋白明显下降(P＜0.05),尿TGF-β1有下降趋势,而对照组无明显差异.结论:肾炎康复片能有效缓解Ⅲ期、Ⅳ期糖尿病肾病患者的临床症状,减少其尿蛋白的排出,这一作用可能与肾炎康复片减少血清C反应蛋白,从而改善糖尿病肾病的微炎症状态.     

高迁移率族蛋白1对狼疮肾炎小鼠肾小球细胞增殖的影响

目的 通过敲低肾组织高迁移率族蛋白1(HMGB1)表达,探讨其对改善狼疮肾炎小鼠肾功能,降低肾小球细胞增殖水平的影响.方法 MRL/Faslpr鼠(n=24)被随机分为模型组、shHMGB1组和空质粒组;选取周龄、体质量相匹配的MRL/MpJ鼠为健康对照组.shHMGB1组和空质粒组采用电穿孔转染技术分别转染shHMGB1质粒和空质粒,模型组和健康对照组仅转染生理盐水.用全自动生化分析仪检测小鼠血清尿素氮和肌酐水平,测定尿蛋白浓度并计算24 h尿蛋白量(UP).HE染色观察肾组织的形态学表现;免疫荧光和Western印迹法检测小鼠肾小球中HMGB1和增殖细胞核抗原(PCNA)的表达;实时定量PCR法检测小鼠肾小球HMGB1和PCNA mRNA表达变化.结果 (1)与健康对照组相比,模型组小鼠肾小球HMGB1 mRNA和蛋白的表达升高(均P＜0.05);与模型组相比,shHMGB1组小鼠肾小球中HMGB1 mRNA和蛋白的表达降低(均P＜0.05).(2)与模型组相比,shHMGB1组小鼠尿蛋白减少(P＜0.05).(3)免疫荧光和Western印迹结果显示,与健康对照组相比,模型组小鼠肾小球中PCNA mRNA和蛋白表达升高(P＜0.05).与模型组相比,shHMGB1组肾小球中PCNA表达降低(P＜0.05).结论 敲低肾组织HMGB1表达可改善狼疮肾炎小鼠的肾功能,降低肾小球细胞的增殖水平.     

狼疮性肾炎患者狼疮活动度与血清维生素D水平变化及意义

目的 观察初发狼疮性肾炎(LN)患者狼疮活动度与血清25-羟-维生素D(25-OH-D)水平的变化,并探讨其临床意义.方法 分别收集了40例初发LN患者的血清标本及其临床资料和40例正常对照组的血清标本.用化学发光法测量患者及正常对照组血清25(OH)D水平,采用t检验、方差分析、spearman相关性分析、Logistic回归分析进行数据分析.结果 LN患者血清25(OH)D水平[(14.71±6.90) ng/mL]相对于正常对照组血清25(OH)D水平[(25.30±2.82) ng/mL]明显偏低,P＜0.05;LN患者血清25(OH)D水平与24h尿蛋白定量呈负相关,r=-0.61,P＜0.05;与抗ds-DNA抗体呈负相关,β=-0.25,P ＜0.05;与补体3(C3)呈正相关,β=0.22,P＜0.05;与补体4(C4)呈正相关,β=0.27,P＜0.05;与SLEDAI呈负相关,β=-0.29,P＜0.05,且随着患者疾病活动度加重,其25(OH)D水平逐渐降低,以上差异均具有统计学意义.与血沉及C反应蛋白(CRP)的升高无相关性,P＞0.05.结论 维生素D可能在LN的发病机制中起重要作用,动态监测LN患者血清维生素D水平,可能有助于监测狼疮活动,判断病情轻重.     

sFlt-1与LAMP-2在ANCA相关性肾炎患者血清中的表达水平及其相关性分析

目的探究可溶性血管内皮细胞生长因子受体1(sFlt-1)与溶酶体相关膜蛋白2(LAMP-2)在抗中性粒细胞胞质抗体(ANCA)相关性肾炎患者血清中的表达水平及其相关性。方法选择2016年10月至2017年10月间90例ANCA相关性肾炎患者作为研究组,根据24h尿蛋白水平分为低蛋白尿组和高蛋白尿组。选择同期单纯慢性肾小球肾炎患者共90例作为对照组以及50例健康者作为健康组。分别比较不同组间的血清和尿液中的sFlt-1和LAMP-2水平,并分别研究sFlt-1和LAMP-2水平与ANCA相关性肾炎以及24h尿蛋白的相关性。结果研究组血清和尿液中的sFlt-1和LAMP-2水平均显著高于对照组和健康组(P0.05)。将尿液和血清中的sFlt-1和LAMP-2纳入Logistic多元回归分析,结果显示血清LAMP-2以及尿液LAMP-2是ANCA相关性肾炎的高危因素(P0.05)。在ANCA相关性肾炎患者(研究组)中,高蛋白尿组患者血清和尿液中的sFlt-1和LAMP-2水平均显著高于低蛋白尿组(P0.05),并且均显著高于健康组(P0.05)。血清和尿液中sFlt-1和LAMP-2与ANCA相关性肾炎患者24h尿蛋白呈现显著的正相关性(P0.05)。结论慢性肾小球肾炎患者血清和尿液中sFlt-1和LAMP-2水平显著升高,ANCA相关性肾炎患者LAMP-2水平显著高于慢性肾小球肾炎患者,并且血清和尿液中LAMP-2是ANCA相关性肾炎的高危因素。     

黄芪当归合剂治疗原发性肾病综合征的临床研究

目的:探讨黄芪当归合剂联合强的松对原发性肾病综合征患者尿蛋白、血象白蛋白、血胆固醇、尿β<,2> 微球蛋白(β<,2>-MG)的影响.方法:将84例原发性肾病综合征患者随机分为治疗纽、对照组各42例,治疗组给予强的松、抗凝等治疗的同时给予黄芪当归合剂治疗;对照组删只给予强的松、抗凝等治疗.检测两蛆治疗前后的24小时尿蛋白、血清白蛋白、血胆固醇、尿β<,2>-MG.结果:治疗组较对照组在治疗过程中,24小时尿蛋白明王下降及血象白蛋白回升在治疗4周后有显著性统计学差异(P<0.05),血胆固醇较对照组在治疗4用后明显下降(P<0.05).尿β<,2>-MG较对照组在治疗4用后明显下降(P<0.05).结论:黄芪当归合剂能有效地增加原发性肾病综合征患者血浆白蛋白水平,降低尿蛋白,并能降低患者血清胆固醇水平,减轻蛋白尿对肾小管、肾问质的损害,但对肾功能的远期保护作用尚待进一步研究.     

原发性肾小球肾炎患者尿蛋白定量与骨转化标志物的相关性研究

目的探讨原发性肾小球肾炎患者尿蛋白定量与骨转化标志物的相关性。方法回顾性分析2012-2014年大连医科大学附属第一医院经肾组织活检确诊为原发性肾小球肾炎患者80例,按照基线尿蛋白定量分3组,A组:24 h尿蛋白定量1g;B组:1.0 g≤24 h尿蛋白定量≤3.5 g;C组:24 h尿蛋白定量3.5 g。记录患者的性别、发病年龄、病程、用药情况。所有研究对象均测定基线、治疗6月时血清Ca、P、ALP、25(OH)D、β-CTX、t PINP、N-MID、CT、i PTH水平,并检测相应时间点血清肌酐和白蛋白水平;同时检测基线和治疗6月时脊柱和股骨头骨密度。结果 3组患者一般情况比较,A、B、C 3组患者血清ALB有明显下降趋势,血清ALB在各组之间比较均有统计学意义(P0.05)。血清Cre、Urea在各组间比较有上升趋势,血清Cre在C组与A组比较明显升高(P0.05),血清Urea在B组与C组比较明显升高(P0.05),差异均有统计学意义。3组患者血清25(OH)D的比较,25(OH)D有明显下降趋势,且A组与B组、A组与C组比较差异均有统计学意义(P0.05),不同蛋白尿组患者血清Ca、ALP、i PTH、N-MID、t PINP、β-CTX在各组间比较均无明显统计学意义。3组患者骨密度值的比较,腰椎T值、腰椎BMD、股骨颈T值、股骨颈BMD随着蛋白尿的增多,均有下降趋势,腰椎BMD在C组与A组比较,明显降低,差异有统计学意义(P0.05)。尿蛋白定量与骨转化标志物的相关性比较,Cox回归表明尿蛋白定量与血清25(OH)D水平呈负相关,与Ca、ALP、i PTH、N-MID、t PINP、β-CTX无关。结论原发性肾小球肾炎患者尿蛋白定量与血清25(OH)D水平呈负相关。     

霉酚酸酯对IgA肾病患者血清和尿液TGF-β1表达的影响

目的 探讨IgA肾病(IgAN)患者血清、尿液TGF-β1表达以及霉酚酸酯(mycophenolate mofetil,MMF)对其表达的影响,揭示MMF治疗IgAN可能的机制.方法 用ELISA法检测健康对照组19例(Ⅰ组)、与MMF组匹配初诊未治疗IgAN 39例(Ⅱ组)、MMF治疗组48例(Ⅲ组)血清、尿液TGF-β1的水平,并比较各组表达差异性.结果 血清中TGF-β1的表达,Ⅱ组较Ⅰ组表达增加(P＜0.05);Ⅲ组较Ⅱ组表达下降(P ＜0.0001).尿液中TGF-β1的表达,Ⅱ组、Ⅲ组均较Ⅰ组表达增加(P＜0.05);Ⅲ组较Ⅱ组表达下降(P＜0.05).IgAN患者血清TGF-β1的表达与病理级别、尿蛋白排泄呈正相关(P=0.044、0.001),尿液TGF-β1的表达与GFR呈负相关(P=0.012),与病理级别、血肌酐、尿蛋白排泄呈正相关(P=0.01、0.013、＜0.0001).血清TGF-β1与尿液TGF-β1的表达呈正相关(P=0.001).IgAN LEE分级≤3级与＞3级的患者相比,后者血清、尿液TGF-β1表达增加,差别有统计学意义(P =0.049,0.028).MMF治疗组疗程3～6个月与≥6个月的患者相比,后者血清、尿液TGF-β1表达下降,差别有统计学意义(P=0.001,0.026).结论 IgAN患者血清、尿液TGF-β1表达显著增加,并且其表达水平与肾功能进展及严重程度等密切相关,MMF可显著下调IgAN患者血清、尿液中TGF-β1表达.因此,血清、尿液TGF-β1可作为预测IgAN疾病进展及评估MMF疗效的重要指标.     

52例狼疮肾炎患者十年随访结果

环磷酰胺(CTX)静脉间断冲击治疗是狼疮肾炎重要的治疗方法.为观察其近、远期不良反应,我们对52例接受CTX静脉冲击治疗的狼疮肾炎患者随访10年,总结相关资料,以期为今后的治疗提供经验.     

Efficacy of low-dose leflunomide in lupus nephritis: A multi-center prospective study

Objective To investigate the efficacy of leflunomide combined with prednisone in the induction therapy of proliferative lupus nephritis (LN). Methods A prospective, multicenter, randomized controlled clinical trial was conducted in patients with biopsy-proved proliferative lupus nephritis recruited from 15 renal centers from 2013 to 2015. Patients were randomized to two groups. Oral leflunomide or intravenous cyclophosphamide was given to patients in each group. Both groups received a tapering course of oral prednisone therapy. All patients were followed up for 24 weeks. The blood biochemistry, urine index, clinical curative effect and adverse reaction were recorded and analyzed statistically. Results A total of 100 patients were enrolled in this clinical trial, including 48 patients in leflunomide group and 52 patients in cyclophosphamide group. After 24 weeks, the overall response rate was 79% (95%CI 67%-90%) in the leflunomide group and 69% (95%CI 56%-82%) in the cyclophosphamide group. 23% (95%CI 11%-35%) of patients in leflunomide group showed complete remission compared with 27% (95%CI 24%-30%) in cyclophosphamide group (P=0.35). The levels of 24-hr urine protein excretion, SLEDAI and anti-dsDNA antibody titers were decreased in patients treated with leflunomide group after 24-weeks treatment. And the levels of serum albumin and complement 3 after treatment were significantly higher compared with these before treatment. There was also no significant difference in changes of 24-hr urine protein excretion, SLEDAI score, anti-dsDNA antibody titers, serum albumin and complement C3 levels after treatment between two groups. Incidence of adverse events did not differ between the leflunomide and cyclophosphamide group. Conclusions Leflunomide combined with prednisone showed same efficacy compared with cyclophosphamide as induction therapy for lupus nephritis. Leflunomide might be an useful medicine in the induction therapy of lupus nephritis.     

亚砷酸对BXSB狼疮鼠狼疮性肾炎的治疗作用

目的:观察亚砷酸对BXSB自发狼疮鼠狼疮性肾炎的治疗作用.方法:2个月龄雄性BXSB小鼠12只,随机分为对照组(生理盐水)和治疗组(亚砷酸0.8mg/kg),隔日腹腔注射,共55 d.观察尿蛋白、尿红细胞、血清肌酐,血清IgG、dsDNA、ANA及肾脏病理变化.结果:治疗组的尿蛋白排出量比对照组明显减少,血清IgG和dsDNA值也比对照组低,肾脏病理改变比对照组明显减轻.结论:亚砷酸能抑制BXSB狼疮鼠的自身免疫反应,对狼疮性肾炎有一定的治疗作用.     

免疫吸附治疗狼疮性肾炎的临床观察

目的 观察免疫吸附治疗狼疮性肾炎的临床疗效.方法 选择2007年7月至2010年7月狼疮性肾炎患者29例,均有明显的血尿、尿蛋白每天＞2.0 g,血肌酐(306.28±0.12)μmol.其中14例狼疮性肾炎患者采用DNA280免疫吸附柱进行血液净化治疗,免疫吸附治疗2次,每次2 h,同时按疗程给与小剂量泼尼松(0.5 mg·kg-1·d-1)及间断环磷酰胺(6～8 g)静脉冲击治疗.另外15例患者应用传统治疗方法,给予大剂量的泼尼松(1 mg·kg-1·d-1)及间断环磷酰胺静脉冲击治疗作为对照组并进行比较.结果 免疫吸附治疗组患者好转率为79%,对照组好转率为56%,两组比较差异有统计学意义(P＜0.01).结论 免疫吸附能有效地控制狼疮性肾炎,明显改善狼疮性肾炎患者的肾功能.

Abstract：

Objective immunoadsorption treatment of lupus nephritis clinical efficacy. Methods from July 2007 to July 2010 29 patients with lupus nephritis, have significant hematuria, urinary protein per day＞ 2.0 g, serum creatinine (306.28 ± 0.12) μmol. 14 patients with lupus nephritis were treated with DNA280 immunosorbent column and blood purification therapy, immunoadsorption therapy 2 times 2 h, while treatment given by a small dose of prednisone (0.5 mg·kg-1·d-1) and intermittent cyclophosphamide (CTX, 6-8 g) intravenous pulse therapy. Another 15 patients were treated with conventional therapy, high dose of prednisone (1 mg · kg-1 · d-1) and CTX intermittent intravenous pulse therapy as a control group and compared. Results improved in patients treated with immunoadsorption was 78.57% in the control group improvement was 56.25% (P ＜ 0.01). Conclusion The adsorption can effectively control the immune lupus nephritis, lupus nephritis significantly improved renal function.     

Colony-Stimulating Factor-1: A Potential Biomarker for Lupus Nephritis

A noninvasive means to predict the onset and recurrence of lupus nephritis (LN) before overt renal injury is needed to optimize and individualize treatment. Colony-stimulating factor-1 (CSF-1) is expressed by kidney tubules at the onset of LN, increases with disease progression, and spills into the circulation in lupus-prone mice. We tested the hypothesis that amplified expression of CSF-1 detected in the serum or urine correlates with intrarenal CSF-1 expression and histopathology (increased macrophage accumulation, activity indices) and clinical kidney disease activity and predicts the onset and recurrence of nephritis in patients with systemic lupus erythematosus (SLE). We found increased serum or urine CSF-1 levels in patients with cutaneous, serositis, and musculoskeletal disease; however, the increase in CSF-1 levels was far greater in LN. Moreover, an elevation in serum or urine CSF-1 levels correlated with increasing intrarenal CSF-1 expression and histopathology. By longitudinally tracking patients, we found that elevated serum CSF-1 heralded the initial onset of disease, and a rise in serum or urine CSF-1 predicted recurrences of LN before clinical evidence of glomerular dysfunction and conventional serologic measures, even in patients with other manifestations of SLE. These findings indicate that serial monitoring for a rise in serum or urine CSF-1 levels in patients with SLE reflects kidney histopathology and may predict renal disease activity and the onset and recurrence of LN more accurately than conventional laboratory measures.     

巨噬细胞移动抑制因子在狼疮肾炎患者血清和尿液中的表达

目的探讨巨噬细胞移动抑制因子（MIF）在狼疮。肾炎（LN）发病过程中的分子生物学机制及其在疾病进展中的作用。方法选择我院LN患者30例，用酶联免疫吸附方法测定LN患者血清和尿液MIF浓度，并将血清和尿液MIF浓度与狼疮活动指数、24h尿蛋白定量、血尿和肌酐清除率（Ccr）进行相关性分析，以20名健康体检者作对照组。结果LN患者血清和尿液MIF浓度均高于对照组（P〈（）．01）；活动期LN患者治疗后尿液MIF浓度较治疗前降低（P％0．（）1），而血清MIF浓度治疗前、后无统计学差异（P〉0．05），活动期较静止期LN患者血清和尿液MIF浓度升高（P〈0．01），LN患者血清和尿液MIF浓度与狼疮活动指数呈正相关（r分别为0．598和0．641，P〈0．01）；LN患者血清和尿液MIF浓度均与24h蛋白尿定量呈显著正相关（r分别为0．524和0．749，P〈0．01），与血尿和Ccr均无相关性（P〉0．05）。结论LN患者尿液MIF浓度明显升高，与病情活动程度相关，对于判断患者病情的活动有一定价值。     

急性时相蛋白在胃癌复发早期诊断中的价值

目的:探讨血清急性时相蛋白变化在评估胃癌患者预后及术后复发早期诊断中的价值。方法:全自动速率散射比浊法检测120名胃癌患者手术前、后血清急性时相蛋白的水平;胃癌根治术87名患者,术后每3个月随访一次,且检测血清急性时相蛋白水平,现察其复发情况,至少随防18个月或至死亡。结果:胃癌组血清C反应蛋白(CRP)、α1-抗胰蛋白酶(α1-AT)和α-酸性糖蛋白(α-AG)水平显著高于健康对照组及良性胃病组(P<0.001),铜蓝蛋白(CER)、转铁蛋白(TFR)和前白蛋白(PAB)水平差异无显著性(P>0.05);胃癌术后一定时期血清CRP、α1-AT和α-AG水平显著低于术前水平(P<0.01或P<0.05),其它指标差异无显著性(P>0.05)。复发组30例,其血清CRP、α1-AT和α-AG水平一定时期后逐渐升高;无复发组57例,其血清CRP/α1-AT和α-AG水平则维持在相对恒定的正常水平,手术前后差异有显著性(P<0.01)。联合检测CRP、α1-AT和α-AG,对复发肿瘤诊断的敏感性、特异性、准确性、阳性预测值和阴性预测值分别达到90.91％、83.33％、90.48％、90.48％和83.33％。结论:联合检测急性时相蛋白可评估胃癌患者的预后,能为胃癌术后复发的早期诊断提供可靠的临床信息。     

Effect of methylprednisolone pulse therapy in patients with lupus nephritis assessed by WHO morphologic classification

To determine indications for treatment with high-dose intravenous methylprednisolone pulse therapy in lupus nephritis, we retrospectively assessed the response to pulse therapy over oral prednisolone administration in 120 biopsy proven lupus nephritis patients according to WHO morphologic classification. In the pulse group, 1 g of methylprednisolone was administered on three consecutive days and oral steroid therapy (40-30 mg) was started. In many occasions in treating class III and IV-b, repeated pulse therapy was performed. In control oral prednisolone group, middle-dose steroid therapy (50-30 mg) was started. In patients with minor glomerular abnormalities and mesangial lupus nephritis, rapid improvement of serological activities was observed in pulse group assessed by serum complement level, anti-DNA antibodies, and anti-nuclear antibodies. In patients with focal lupus nephritis, rapid rise in serum complement level and fall in proteinuria was observed in the pulse group. In patients with diffuse proliferative lupus nephritis with active necrotizing lesions, faster rise in serum complement level and proteinuria were observed in the pulse group. In patients with membranous lupus nephritis there was no significant difference between two groups. In comparison with the effect of pulse therapy among each morphologic class, the rise of serum complement level was slowest in class IV-b. Both group of IV-b and V manifested nephrotic syndrome and by pulse therapy the decrease in urinary protein was faster and more significant in class IV-b compared with class V. No significant adverse effect of methylprednisolone was observed during about 150 times of pulse therapy. Bacterial, viral infections such as herpes zoster and fungal infections were observed in pulse group as often as control group.     

趋化因子SDF-1a生物半衰期预测乳腺癌术后复发及转移

目的 探讨乳腺癌患者手术及化疗后血清趋化因子SDF-1a的动态变化,评价利用SDF-1a的半衰期(T1/2)预测乳腺癌术后复发及转移的价值.方法 回顾性分析112例同一医疗组收治的乳腺癌患者,分别检测乳腺癌改良根治术术前、术后以及每次化疗前1天的血清趋化因子SDF-1a的含量,观察治疗后SDF-1a的动态变化并计算其半衰期,分析其与乳腺癌治疗后复发、转移的相关性.结果 乳腺癌治疗后无复发转移组85例,手术以及化疗后血清SDF-1a逐渐下降至正常水平;而复发转移组27例SDF-1a下降缓慢,并维持在较高水平;复发转移组的SDF-1a半衰期较无复发转移组明显延长(P＜0.01);取半衰期≥14 d预测乳腺癌治疗后复发转移的敏感性、特异性和准确度分别为81.5%、70.6%及73.2%.结论 乳腺癌治疗后血清SDF-1a的动态变化与肿瘤的复发转移密切相关.检测血清SDF-1a半衰期对于预测乳腺癌复发转移有临床价值.     

Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis

Noninvasive molecular tests of urine cells have been developed to monitor the activity of kidney diseases. We evaluate whether measurement of urinary messenger RNA (mRNA) levels of chemokine and growth factor genes could distinguish between diffuse proliferative lupus nephritis (class IV LN) and others and whether it is able to predict the response to therapy. Prebiopsy urine samples were collected from 26 LN patients. Urine specimens were serially collected over a period of 6 months from class IV LN patients who were receiving standard immunosuppressive treatments. Urinary interferon-producing protein 10 and its CXC chemokine receptor (CXCR)3, transforming growth factor-beta (TGF-beta), and vascular endothelial growth factor (VEGF) mRNA levels were analyzed by quantitative real-time polymerase chain reactions. Levels of chemokine or growth factor mRNAs in urine could distinguish class IV LN from others, with a sensitivity of 85% and a specificity of 94%. The receiver-operative characteristic curve demonstrated that urine mRNA levels of these genes could identify active class IV LN with an accuracy greater than the current available clinical markers, namely systemic lupus erythematosus (SLE) disease activity index, proteinuria, renal function, or urinalysis. A significant reduction of interferon-producing protein 10 (IP-10), CXCR3, TGF-beta, and VEGF mRNA levels from baselines was observed in patients who responded to therapy, whereas the levels tended to increase in those who resisted to treatment. Measurement of urinary chemokine and growth factor mRNAs can precisely distinguish class IV LN from others. Temporal association between these markers and therapeutic response is demonstrated. This noninvasive approach serves as a practical tool in diagnosis and management of LN.     

霉酚酸酯对狼疮性肾炎的治疗效果及肾脏病理分析

目的研究探讨霉酚酸酯(MMF)对狼疮性肾炎(LN)的临床治疗效果。方法收集2008年1月至2017年12月于本院治疗的40例LN患者,应用数字随机表法将其随机分为两组,每组20例。对照组采用环磷酰胺治疗,观察组采用霉酚酸酯治疗,比较两组的临床疗效、不良反应、治疗前后的疾病活动度指数、肾功能指标及肾脏病理指标。结果两组的总有效率比较差异无统计学意义(P>0.05),观察组的总有效率高于对照组(P<0.05)。治疗前,两组的疾病活动度指数、血肌酐(Scr)、尿素氮(BUN)、24 h尿蛋白、纤维新月体、白金耳和微血栓差异均无统计学意义(P>0.05),治疗后,与对照组比,观察组的疾病活动度指数、BUN、Scr、24 h尿蛋白和总不良反应发生率均明显降低(P<0.05)。两组患者的纤维新月体、白金耳和微血栓均明显降低,但组间比较差异无统计学意义(P>0.05)。结论霉酚酸酯治疗狼疮性肾炎可以达到与环磷酰胺相当的临床疗效,霉酚酸酯相比于环磷酰胺可以减少患者不良反应,其安全性更加安全可靠。